SEA BASS & SEA BREAM
The consolidation of Mediterranean aquaculture is standardizing production practices in the region and leading to better biosecurity management, but growing out fish in the unforgiving environment at sea poses the sort of challenge that demands realistic, practical solutions.
Analyzing proteins from the skin mucus of gilthead seabream (Sparus aurata) could offer a promising, welfare-friendly route to monitor stress levels of the fish during production cycles.
An interview with Emre Berke, DVM, PhD, field technical support associate for PHARMAQ.
The microbiome of gilthead seabream farmed in the Mediterranean appears to be very distinct from that of their surrounding environment — offering new insight which may help in managing health issues associated with the species.
A new study analyzing three strains of the bacterium Vibrio harveyi found among farmed sea bass in the Mediterranean has underlined the diversity of the pathogen, which poses a severe threat to the region’s aquaculture.
No effective licensed therapies exist against amyloodiniosis, a disease of fish species caused by Amyloodinium ocellatum (AO) ectoparasites. However, new research has shown that European sea bass (ESB) can develop specific immunity to the disease, which could in turn lead to the development of vaccines.
With technologies for molecular diagnosis of fish disease increasingly available, sometimes simpler approaches that have great diagnostic power are being ignored.
Improving standards on Mediterranean fish farms is driving interest in Tricaine PHARMAQ — the only authorized fish anesthetic product.
Aquaculture in Greece has endured some ups and downs since its establishment in the 1980s, from the Greek financial crisis to the Covid-19 pandemic.
Barramundi has much potential as a sustainable fish in the marine tropics — but health challenges remain for producers. Josh Goldman, CEO of Australis, explains his company’s approach.